BIO-RAD LABORATORIES, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $28.1m $122.2m $365.6m $1.8b $3.8b $4.2b ($3.6b) ($637.3m) ($1.8b) $759.9m
Depreciation, Depletion and Amortization $142.9m $148.7m $138.1m $134.2m $138.1m $133.8m $137.3m $145.9m $151.6m $165.4m
Amortization of Intangible Assets $35.2m $30.8m $28.3m $23.5m $27.5m $28.4m $24.9m $23.8m $21.2m $23.8m
Depreciation $141.4m
Depreciation, Amortization and Accretion, Net $40.3m $37.1m $39.3m $39.9m $46.5m $41.2m $40.0m
Deferred Income Tax Expense (Benefit) ($51.2m) ($84.8m) $120.9m $450.2m $979.0m $1.1b ($1.2b) ($322.6m) ($626.8m) $170.5m
Share-based Payment Arrangement, Noncash Expense $19.7m $23.4m $27.8m $35.6m $41.6m $51.2m $60.9m $61.3m $62.3m $58.0m
Payment, Tax Withholding, Share-based Payment Arrangement $8.9m $8.1m $12.9m $22.5m $14.0m $14.9m $3.4m $3.0m
Share-based Payment Arrangement, Expense $19.7m $23.4m $27.8m $35.6m $41.6m $51.2m $60.9m $61.3m $62.3m $58.0m
Equity Method Investment, Other than Temporary Impairment $800k $11.9m $0 $0 $6.0m
Goodwill, Impairment Loss $13.5m $11.5m $282.0m $0 $0 $0 $0 $0
Impairment of Intangible Assets (Excluding Goodwill) $172.8m
Impairment of Intangible Assets, Finite-lived $0 $0 $0 $0 $0 $0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $46.4m
Gain (Loss) on Disposition of Assets $4.1m $0 $0
Gain (Loss) on Disposition of Business ($11.7m) $0 ($1.4m) ($2.5m) $0 $0
Gain (Loss) on Disposition of Other Assets $5.1m $0 $11.7m $0 $1.4m $0 $0
Gain (Loss) on Disposition of Property Plant Equipment ($600k) ($8.1m) ($2.0m) ($1.2m) ($1.1m) ($120.8m) ($112.8m) ($156.7m) ($165.6m) ($157.6m)
Income Tax Expense (Benefit) $13.4m ($24.4m) $147.0m $502.4m $1.1b $1.2b ($1.1b) ($212.8m) ($498.3m) $235.6m
Other Nonoperating Income (Expense) $14.8m $12.2m $36.6m $26.1m $24.5m $26.8m $44.6m $106.4m $90.3m $90.3m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable ($12.5m) $64.1m ($59.7m) ($1.6m) $15.0m $20.4m $87.4m ($11.4m) ($16.2m) ($19.6m)
Increase (Decrease) in Inventories $57.1m $47.7m $12.9m ($24.2m) $52.1m ($46.1m) $158.8m $46.3m ($8.5m) ($68.9m)
Debt and Equity Securities, Gain (Loss) $1.6m $1.5m $700k
Debt and Equity Securities, Unrealized Gain (Loss) $4.9b ($5.2b) ($1.3b) ($2.7b) $900.4m
Fair Value, Option, Changes in Fair Value, Gain (Loss) $100.6m $6.8m ($12.5m) ($12.4m)
Foreign Currency Transaction Gain (Loss), before Tax ($4.5m) ($9.1m) ($2.9m) ($2.2m) ($1.8m) ($2.8m) $205k $7.3m $3.9m $6.6m
Foreign Currency Transaction Gain (Loss), Realized ($19.9m) $9.9m ($20.7m) $43.5m
Goodwill $477.1m $506.1m $219.8m $264.1m $291.9m $347.3m $406.5m $413.6m $410.5m $579.8m
Marketable Securities, Unrealized Gain (Loss) ($2.7b) $900.4m
Nonoperating Income (Expense) $0
Provision for Loan, Lease, and Other Losses $7.5m $0 $0 $1.4m
Realized Investment Gains (Losses) $800k $100k $1.6m $1.5m $1.0m $8.0m $2.3m $700k $6.7m $1.0m
Revenue from Contract with Customer, Including Assessed Tax $2.3b $2.3b $2.5b $2.9b $2.8b $2.7b $2.6b $2.6b
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement ($1.2m) $0 ($900k) ($1.3m) $1.2m ($200k) ($1.3m) ($2.2m) ($1.3m)
Net Cash Provided by (Used in) Operating Activities $216.4m $103.9m $285.5m $457.9m $575.3m $656.5m $194.4m $374.9m $455.2m $532.2m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $141.4m $111.3m $129.8m $98.5m $98.9m $120.8m $112.8m $156.7m $165.6m $157.6m
Payments to Acquire Investments $278.1m $282.7m $371.0m $371.4m $248.5m $851.6m $2.1b $689.0m $1.3b $669.3m
Payments for (Proceeds from) Other Investing Activities ($3.4m) $0 $1.4m $0 $0
Net Cash Provided by (Used in) Investing Activities ($213.9m) ($175.6m) ($187.0m) ($208.9m) ($60.2m) ($784.4m) ($1.2b) $20.2m ($160.2m) ($189.7m)
Cash flows from financing activities:
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale $143.0m $202.2m $225.3m $226.9m $278.3m $341.4m $357.8m $361.3m $199.3m $62.0m
Repayments of Long-term Debt $303k $316k $3.0m $643k $426.9m $3.0m $510k $467k $400k $500k
Proceeds from Issuance of Common Stock $11.3m $7.3m $14.1m $5.0m $7.3m ($1.9m) ($3.4m) $18.5m $19.2m $15.8m
Payments for Repurchase of Common Stock $2.9m $48.9m $28.0m $100.0m $50.0m $215.7m $428.7m $203.6m $295.5m
Net Cash Provided by (Used in) Financing Activities $9.0m $341k ($48.7m) ($22.8m) ($523.0m) ($55.4m) $973.6m ($425.6m) ($218.8m) ($283.2m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4.5m ($196.0m) ($36.6m) ($30.2m) $85.4m $42.4m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $434.2m $662.7m $667.1m $471.1m $434.5m $404.4m $489.8m $532.2m
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $38.4m $52.1m $62.4m $45.1m $65.2m $134.7m $158.3m $129.6m $99.4m $61.6m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.